5 Key Takeaways

• 1

  The VisiPlate glaucoma drainage device achieved a 40% reduction in mean intraocular pressure at 6 months in a clinical trial.

• 2

  Seventy-eight percent of subjects experienced over a 20% reduction in IOP with fewer medications after receiving the VisiPlate.

• 3

  The VisiPlate demonstrated a favorable safety profile with no serious adverse events reported during the trial.

• 4

  The device's unique design features multiple channels that promote a diffuse outflow of aqueous, reducing discomfort for patients.

• 5

  Avisi Technologies is pursuing FDA approval for the VisiPlate, which could become a significant advancement in glaucoma treatment.